4-Antibody is expected to use its proprietary and unencumbered Hu-PAC and Retrocyte Display technologies for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim.
As per the agreement, 4-Antibody will receive payments of up to EUR177.5m including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones.
Ulf Grawunder, co-founder and CSO at 4-Antibody, said: “This is a landmark agreement for 4-Antibody. We are delighted to commence a long-term collaboration with Boehringer Ingelheim and to apply the strength of 4-Antibody’s fully human antibody discovery and engineering platforms to create valuable potential new drug candidates.
“Our unique and unencumbered technology capabilities allow the efficient generation of novel or improved fully human antibodies against any target class for our collaboration partners and for our own clinical development pipeline.”